NASDAQ:SBFM Sunshine Biopharma (SBFM) Stock Price, News & Analysis $1.15 -0.05 (-4.17%) Closing price 04:00 PM EasternExtended Trading$1.17 +0.02 (+2.09%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Sunshine Biopharma Stock (NASDAQ:SBFM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sunshine Biopharma alerts:Sign Up Key Stats Today's Range$1.14▼$1.2150-Day Range$1.15▼$2.4352-Week Range$1.10▼$24.30Volume102,029 shsAverage Volume847,012 shsMarket Capitalization$575 thousandP/E RatioN/ADividend YieldN/APrice Target$70.00Consensus RatingHold Company Overview Sunshine Biopharma, Inc. is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors. Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies. These molecules are engineered to enhance tumor selectivity and minimize cardiotoxicity commonly associated with traditional anthracyclines. The company is headquartered in Montreal, Canada, and operates research facilities in North America. Sunshine Biopharma collaborates with academic institutions and contract research organizations to conduct preclinical studies and regulatory activities. Leadership is headed by Dr. Bhupinder Kaur Singh, who serves as President and Chief Executive Officer, guiding corporate strategy, research priorities and investor relations.AI Generated. May Contain Errors. Read More Sunshine Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreSBFM MarketRank™: Sunshine Biopharma scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingSunshine Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialSunshine Biopharma has a consensus price target of $70.00, representing about 5,987.0% upside from its current price of $1.15.Amount of Analyst CoverageSunshine Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Sunshine Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sunshine Biopharma is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sunshine Biopharma is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSunshine Biopharma has a P/B Ratio of 0.02. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.33% of the float of Sunshine Biopharma has been sold short.Short Interest Ratio / Days to CoverSunshine Biopharma has a short interest ratio ("days to cover") of 0.82, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sunshine Biopharma has recently increased by 102.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSunshine Biopharma does not currently pay a dividend.Dividend GrowthSunshine Biopharma does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.78 News SentimentSunshine Biopharma has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sunshine Biopharma this week, compared to 1 article on an average week.Search Interest4 people have searched for SBFM on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Sunshine Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders0.48% of the stock of Sunshine Biopharma is held by insiders.Percentage Held by Institutions41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sunshine Biopharma's insider trading history. Receive SBFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SBFM Stock News HeadlinesSunshine Biopharma (SBFM) Expected to Post Earnings on TuesdayAugust 10, 2026 | americanbankingnews.comEXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug ApprovalAugust 4, 2026 | benzinga.comMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.August 14 at 1:00 AM | Paradigm Press (Ad)Sunshine Biopharma Inc.: Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and VomitingJuly 30, 2026 | finanznachrichten.deSunshine Biopharma Inc.: Sunshine Biopharma and University of Arizona Publish Significant New Research FindingsJuly 20, 2026 | finanznachrichten.deSBFM Share News TodayMay 15, 2026 | uk.investing.comSunshine Biopharma Delays Annual SEC FilingApril 14, 2026 | theglobeandmail.comSunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidoneOctober 28, 2025 | msn.comSee More Headlines SBFM Stock Analysis - Frequently Asked Questions How have SBFM shares performed this year? Sunshine Biopharma's stock was trading at $12.30 at the beginning of 2026. Since then, SBFM shares have decreased by 90.7% and is now trading at $1.15. How were Sunshine Biopharma's earnings last quarter? Sunshine Biopharma, Inc. (NASDAQ:SBFM) issued its quarterly earnings data on Thursday, August, 13th. The company reported ($1.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.05. The company earned $9.26 million during the quarter, compared to analyst estimates of $8.70 million. Sunshine Biopharma had a negative net margin of 18.45% and a negative trailing twelve-month return on equity of 27.75%. When did Sunshine Biopharma's stock split? Sunshine Biopharma shares reverse split on the morning of Wednesday, April 17th 2024.The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Sunshine Biopharma? Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sunshine Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Abbott Laboratories (ABT), Energy Select Sector SPDR Fund (XLE), Bank of America (BAC) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/13/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (54m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 SBFM's financial health is in the Red zone, according to TradeSmith. SBFM has been in this zone for over 54 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SBFM CIK1402328 Webwww.sunshinebiopharma.com Phone(514) 426-6161FaxN/AEmployees3Year Founded2006Price Target and Rating Average Price Target for Sunshine Biopharma$70.00 High Price Target$70.00 Low Price Target$70.00 Potential Upside/Downside+5,987.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($12.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.97 million Net Margins-17.94% Pretax Margin-16.84% Return on Equity-27.69% Return on Assets-21.26% Debt Debt-to-Equity RatioN/A Current Ratio4.22 Quick Ratio1.98 Sales & Book Value Annual Sales$36.31 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value$46.93 per share Price / Book0.02Miscellaneous Outstanding Shares500,000Free Float499,000Market Cap$575 thousand OptionableNot Optionable Beta1.16 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:SBFM) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredYour 10X AI demo is starting…Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...TradeSmith | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWho Really Gets Rich from IPOs?Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
